% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • summer2762 summer2762 Mar 11, 2011 3:03 PM Flag

    The nsclc trial is now 35% larger

    The bad news is, because of the additional patients, its completion date is now 3+yrs away (per cc). However, the good news is that it now has an interim efficacy analysis.

    The co avoids giving any indication about the progress in the other trials as if they were state secrets.

    No additional news, which is the most important good news.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think Teva is bearing the cost of enrolling those additional 250 patients, since under the partnership agreement OGXI's contribution to all the P3 trials for OGX-011 is limited to $30mm. Of course, with two futility analyses and an interim efficacy analysis planned, there's a fair chance the trial will end early, and whether the ending is good or bad the trial cost would be reduced. So it's a clever strategy on Teva's part.

      If the lung trial goes the distance OGXI is now saying it will continue beyond 2014 when their current cash will run out, assuming there are no new partnerships (e.g. for 427). So in a sense we the stockholders will bear the cost of the expansion of the trial size since if there's no early ending or new partnership OGXI will need to do another financing. They were probably going to do one before 2014 anyway though.

      I don't understand their refusal to provide enrollment updates or project when trial results may be available. I think it just leads people to assume that things are progressing slowly.

0.46-0.09(-16.38%)Oct 27 3:59 PMEDT